Akorn, Inc. Announces Supplemental New Drug Application Approval for Sufenta(R) (Business Wire via Yahoo! Finance)
BUFFALO GROVE, Ill.----June 7, 2006--Akorn, Inc. today announced that it has received a supplemental new drug application approval for Sufenta injection. Akorn is the NDA holder of the drug product Sufenta , which has been off the market since 2002 due to compliance issues associated with the Decatur manufacturing facility.

Avanir Pharma submits new Neurodex data to FDA (San Diego Daily Transcript via Yahoo! News)
San Diego-based Avanir Pharmaceuticals (Nasdaq: AVNR, News) announced Monday the submission of additional data from its ongoing open label study assessing safety in chronic exposure to Neurodex, an investigational new drug that is the subject of a new drug application (NDA).